Description

Fragment 176-191, CJC-1295 & Ipamorelin Peptide Blend

The Fragment 176-191, CJC-1295, and Ipamorelin peptide blend combines three research compounds frequently investigated for their potential influence on growth hormone pathways, body composition, and metabolic activity. Researchers have explored these peptides both individually and in combination due to their distinct mechanisms of action and the possibility of complementary effects on growth hormone regulation.

CJC-1295 is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH) composed of 29 amino acids. Designed to mimic the active portion of natural GHRH, it contains several structural modifications intended to improve stability and prolong activity. Many formulations also incorporate a Drug Affinity Complex (DAC), which may extend circulation time by allowing the peptide to associate with plasma proteins.

Ipamorelin is a selective growth hormone secretagogue (GHS) consisting of five amino acids. Researchers suggest it may stimulate growth hormone release by interacting with Growth Hormone Secretagogue Receptor-1a (GHS-R1a), the same receptor activated by the naturally occurring hormone ghrelin. This interaction has made Ipamorelin a popular subject of investigation in studies focused on growth hormone signaling and metabolic regulation.

Fragment 176-191, sometimes referred to as AOD 9604, is a modified segment of human growth hormone consisting of 15 amino acids. Research suggests that this peptide may selectively influence pathways involved in lipid metabolism, particularly through interactions with beta-3 adrenergic receptors. These mechanisms have led investigators to examine its potential role in fat utilization and thermogenic activity.

When combined, these three peptides may influence growth hormone-related pathways through multiple mechanisms, potentially supporting balanced hormone signaling, body composition regulation, and metabolic function.

Chemical Profile

Molecular Formula

Fragment 176-191: C78H125N23O23S2
CJC-1295 (Mod GRF 1-29): C152H252N44O42
Ipamorelin: C38H49N9O5

Molecular Weight

Fragment 176-191: 1817.12 g/mol
CJC-1295 (Mod GRF 1-29): 3367.9 g/mol
Ipamorelin: 711.8 g/mol

Alternative Names

Fragment 176-191: AOD 9604, hGH Lipolytic Fragment, Somatostatin (177-191) Tyrosyl
CJC-1295: Mod GRF 1-29, CJC-1295 Without DAC
Ipamorelin: Ipamorelin Acetate, IPA

Research and Scientific Literature

Growth Hormone Signaling

Among the three compounds, CJC-1295 and Ipamorelin are primarily studied for their ability to stimulate endogenous growth hormone release, while Fragment 176-191 is derived directly from the growth hormone molecule itself.

Clinical investigations evaluating CJC-1295 have reported significant increases in circulating growth hormone concentrations. In one study involving healthy adult participants, researchers observed substantial elevations in growth hormone levels that persisted for several days following administration.(4)

A separate dose-escalation trial reported concentration-dependent increases in growth hormone secretion, along with corresponding rises in insulin-like growth factor-1 (IGF-1), a key mediator of growth hormone activity.(5)

Ipamorelin has demonstrated similar activity in research settings. Pharmacokinetic investigations suggest that a single administration may produce marked increases in circulating growth hormone levels compared with placebo conditions.(6)

Together, CJC-1295 and Ipamorelin continue to be investigated for their potential synergistic effects on endogenous growth hormone production.

Fat Metabolism and Weight Management

Fragment 176-191 has attracted considerable attention for its potential role in lipid metabolism. In a large clinical study involving approximately 300 participants, researchers evaluated the peptide over a 12-week period across multiple dosing groups.

Study findings suggested measurable reductions in body weight among participants receiving the peptide compared with placebo. Researchers also noted favorable trends involving cholesterol markers and glucose regulation during the study period.(7)

These findings have encouraged ongoing exploration into Fragment 176-191 as a research tool for understanding metabolic regulation and adipose tissue activity.

Tissue Repair and Cartilage Research

The regenerative potential of Fragment 176-191 has also been examined in preclinical models.

In one study involving experimental rabbit models with induced cartilage degeneration, investigators compared Fragment 176-191, hyaluronic acid, and combination treatments. Animals receiving both Fragment 176-191 and hyaluronic acid demonstrated the most favorable cartilage outcomes among the treatment groups.(8)

Researchers concluded that the peptide may contribute to cartilage regeneration processes, particularly when used alongside supportive compounds such as hyaluronic acid.

Body Composition and Lean Mass

The three peptides included in this blend have been studied for different aspects of body composition.

Research suggests that Fragment 176-191 may support reductions in adipose tissue through mechanisms linked to fat metabolism. Meanwhile, Ipamorelin has been associated with increases in body weight and appetite, likely due to its interaction with ghrelin-related signaling pathways.

Experimental studies have reported modest increases in body weight and fat-pad mass following Ipamorelin exposure, indicating a potential influence on both appetite and energy storage.(9)

By contrast, CJC-1295 has demonstrated potential to support lean tissue development. Studies involving growth hormone-deficient animal models found that exposure to CJC-1295 helped maintain lean mass and normal growth characteristics while limiting excessive adipose accumulation.(10)

Because Fragment 176-191 and CJC-1295 are often associated with favorable body composition outcomes, researchers continue to investigate whether they may complement the growth hormone-releasing activity of Ipamorelin while offsetting some of its appetite-related effects.

Bone Mineral Content

Growth hormone secretagogues have also been examined for their possible impact on skeletal health.

Research involving Ipamorelin demonstrated increases in bone mineral content within experimental models, particularly in the femur and vertebral regions. Advanced imaging analysis suggested that improvements in bone measurements may have been linked to increases in bone size and cortical bone area rather than changes in volumetric bone density.(11)

These findings have contributed to broader interest in growth hormone-related peptides as subjects for ongoing skeletal and metabolic research.

Fragment 176-191, CJC-1295 & Ipamorelin Peptide Blend from Medlabs Peptides is intended exclusively for laboratory and scientific research purposes. Please review all applicable terms and conditions before purchase.